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Should Hypopharynx Cancer Continue to be 
Included in “Multi-Head and Neck” Trials 
within the RTOG?
Purpose/Objective(s)
It is becoming increasingly evident that the behavior of cancers from 
different subsites of the head and neck varies greatly despite similar 
histologic appearance. As current head and neck trials are focusing 
more on a risk-based approach, it is unclear into which trials patients 
with hypopharyngeal primaries (HP) should be included. Thus, we 
undertook to examine whether patients with HP perform as well as 
oropharyngeal primaries (OP) in the definitive setting and whether 
HP perform as well as larynx primaries (LX) in the post-operative 
setting in the multi-institutional setting.
Materials/Methods
We investigated two situations. First, in the definitive setting of RTOG 
9003 (RT: 4 regimens), we limited our analysis to those OP cancer 
patients with >10 year smoking history to minimize the potential 
confounder of HPV positivity, a known good prognostic marker. In 
the postoperative setting of RTOG 9501 (RT vs. CRT) we compared 
HP cancer vs. LX cancer. The effects of primary site on disease-free 
and overall survival (DFS, OS) and pattern of failure (local regional 
control, LC, and distant metastases, DM) were evaluated using Cox 
proportional hazards models adjusted for primary site, T stage, N 
stage, treatment, and KPS. Logistic regression was used to model the 
probability of Grade 3-5 late toxicity (> 90 days from start of radiation 
therapy) in HP patients as compared to other sites.
Results
A total of 108 HP and 605 OP were analyzed from RTOG 9003. In 
RTOG 9501, 40 HP and 86 LX primaries were analyzed. 
In the definitive setting, when limiting OP to those with > 10 pack-
years, there is some indication that HP has worse OS [HR 1.14 (0.91-
1.43)] and DFS [HR 1.2 (0.96-1.5]. There was no indication of worse 
LC or DM rate.
In the postoperative setting, HP did not have worse outcomes to 
patients with LX in terms of OS [HR 1.09 (0.69-1.7)], DFS [HR 1.01 
(0.65-1.57)], LC [HR 1.15 (0.53-2.5)], and DM [HR 1.3 (0.75-2.26)].
There is no indication that HP patients have more Grade 3-5 late 
toxicity than other sites in either the postoperative or definitive setting.
Conclusion
Patients with primary HP carcinoma have worse OS, and DFS, in the 
definitive setting in comparison to OP patients with greater than 10 
year smoking history. In the postoperative setting, patients with HP 
have similar outcomes to LX patients. This suggests that HP patients 
do not require separate trials, but consideration should be given to 
stratification by disease site in future multi-H&N trials. 
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